WO1998012303A1 - Method of cell culture - Google Patents
Method of cell culture Download PDFInfo
- Publication number
- WO1998012303A1 WO1998012303A1 PCT/AU1997/000616 AU9700616W WO9812303A1 WO 1998012303 A1 WO1998012303 A1 WO 1998012303A1 AU 9700616 W AU9700616 W AU 9700616W WO 9812303 A1 WO9812303 A1 WO 9812303A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- neuronal
- tissue
- agent
- population
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
Definitions
- the present invention relates to a method of culturing a primary mixed population of neuronal and glial cells.
- the present invention also relates to methods of screening neuronal growth factors, neuroprotective agents, neurotoxins, therapeutic or prophylactic agents and agents that affect the activity of cells.
- Primary cultures of neurons have many advantages over established immortalised cell lines in terms of providing model systems for studying neurogenesis and cell death. These advantages include the ability to maintain a reasonably true phenotype and the ability to undergo neurogenesis and senescence in culture. Mixed primary cultures of neuronal and glial cells provide even further advantages. These heterogeneous cell populations more accurately reflect the normal tissue of origin and therefore allow studies of processes which parallel normal behaviour. Heterogeneous cell cultures also allow expression of receptors and growth factors which may not be homogeneous throughout the tissue. The heterogeneity of the cells, both in cell type and stage of development, is therefore a further advantage in model cell cultures.
- the present inventor has now devised a cell culture method which provides primary cultures of heterogeneous neuronal and glial cell populations which have relatively long term viability (ie. the cells survive for up to three weeks in culture and then senesce) and which may be maintained in a serum-free environment.
- the present invention provides a method of culturing a mixed population of neuronal and glial cells which method includes
- tissue sample which includes a heterogeneous population of neuronal and glial cells
- the tissue sample is olfactory neuroepithelial tissue.
- the tissue sample may be derived from a variety of animal sources.
- the tissue sample may be derived from a chicken, rat or frog.
- Preferred animal sources are mammals such as rats, mice, primates and humans.
- the tissue sample is derived from a rat.
- the tissue is derived from a neonatal rat.
- the tissue sample may be obtained by dissection as is known in the art.
- the tissue is minced to provide small pieces of tissue prior to the step of enzymatic dissociation.
- the small pieces of tissue may be of sizes of approximately 1 mm 2 .
- the enzymatic dissociation involves the use of one of more enzymes selected from the group consisting of dispase, collagenase, hyaluronidase and DNAse. Typically these enzymes are incubated with the tissue at 37°C to digest the substances which may bind and aggregate the cells to each other.
- the dissociation of neuronal and glial cells further includes mechanical disruption.
- the mechanical disruption may include any means known in the art, such as trituration, Waring blender, Potter-Elvenhjem homogenizer, meat grinders, shakers etc.
- the mechanical disruption involves trituration.
- the separation of the dissociated cells involves a size fractionation procedure.
- the size fractionation procedure may involve selective filtering of neuronal and glial cells.
- the filtering involves passing the cells through a first filter which has a pore size of from 40 to 60 ⁇ m and through a second filter which has a pore size of from 8 to 15 ⁇ m.
- the first filter has a pore size of
- the filters may be made of any materials although wire and nylon meshes are preferred.
- the separated cells may be resuspended in appropriate nutrient media.
- the resuspension media may, for example include supplements such as serum.
- the resuspension media includes glutamate supplementation and an agent to inhibit the overgrowth of dividing cells.
- the support means is a solid substrate such as glass slide, a plastic slide, a glass tissue culture dish or a plastic tissue culture dish.
- the support means is coated with one or more matrix substances selected from the group consisting of laminin, fibronectin and Matrigel.
- the matrix substance is laminin.
- the nutrient media may be decanted and replaced with a serum-free media.
- the cell culture is then maintained by feeding with serum-free media.
- the serum-free nutrient media includes a commercial media preparation with a valine supplement, such as MEM D-val [Gibco]. and a serum free supplement, such as Monomed A (CSL).
- the present invention provides a cell population which has been cultured by a method according to the first aspect of the present invention.
- the cell culture system of the present invention provides a valuable tool in the study of isolated cells and in the study of neuronal-glial interactions which is not feasible in an explant culture of a piece of whole tissue.
- the cell populations are heterogeneous, as occurs in normal tissue, and therefore allow the study of processes which parallel normal behaviour.
- the present inventor has also found that neuronal cells cultured according to the present invention have extensive neurite outgrowth making them suitable for studies of axonal outgrowth and growth cones in vitro. Further advantages of the present invention are that the cell culture system is maintained in serum-free conditions and that there are no exogenous growth factors required for maintenance.
- the cell culture system of the present invention therefore provides a means for testing the effectiveness of known neuronal and glial growth factors and also for screening novel growth factors.
- the system also provides a means for screening and measuring the effects of neurotoxins and potential neuroprotective agents.
- the system further provides a means for screening for any agent which affects the activity of cells.
- activity we mean any activity of interest, examples of which include differentiation and intercellular communication.
- the cell culture system of the present invention provides a means for screening for therapeutic or prophylactic agents which may be used to treat or prevent a range of disease states. Such disease states may include neurodegenerative disorders such as Parkinson's Disease.
- the present invention provides a method of screening an agent for neurotoxic or neuroprotective activity which method includes addition of the agent to a population of cells cultured by a method according to the first aspect of the present invention.
- the present invention provides a method of screening an agent for activity which affects the growth of cells which method includes addition of the agent to a population of cells cultured by a method according to the first aspect of the present invention.
- the present invention provides a method of screening for an agent which affects the activity of cells which method includes adding a putative agent to a population of cells cultured by a method according to the first aspect of the present invention and monitoring the activity of the cell population.
- the present invention provides a method of screening for a therapeutic or prophylactic agent which method includes addition of a putative therapeutic or prophylactic agent to a population of cells cultured by a method according to the first aspect of the present invention.
- the present inventor has detected (by RT-PCR) mRNAs for a variety of odorant receptors in olfactory neurons cultured by the method of the present invention. This observation confirms that cells cultured by the present method have the genetic machinery to express odorant receptor proteins. Accordingly, the culture method of the present invention is also potentially useful for studies of odorant receptor function.
- odorants are compounds which have the ability to stimulate neuronal cells above their basal level of excitement.
- the culture method of the present invention may therefore be used to screen for odorants and antagonists of oderants. Antagonism may be readily determined by exposing the cultures of the present invention to the odorant alone, and to the odorant in admixture with a potential antagonist.
- the culture method of the present invention may also be useful for producing cells for transplantations or for nerve repair operations or acute therapies for spinal cord injury.
- the cultured cells may be induced to express a neurotrophic factor, such as GDNF, which has been shown to play an important role in olfactory neurons [Buckland, M., Pemper, F & Cunningham, A. (1998) GDNF: A Complex Trophic Role in the Olfactory System. St Vincents Hospital Symposium, Sept, Sydney; Bucldand, M. & Cunningham, A.
- dispase 11 (Boehringer Mannheim) 6,2 mg/ml, collagenase D (Boehringer Mannheim) 1.12 mg/ml, hyamronidase (Sigma) 0.9 mg/ml, Dnase 1 (Sigma) a sprinkle of powder. Filter through 0.45 ⁇ m and 0.22 ⁇ m filters. Aspirate off supernatant leaving about 200ml of DMEM-air. Place tissue pieces into 10cm petri dish. Mince tissue with sterile scissors for 5 mins then add filtered enzymes.
- tissue to a sterile conical flask containing a small stirring bar and incubate solution for 60 mins at 37oC in a water bath, Wet a wire mesh [150 ⁇ m, Small Parts, Inc] with DMEM-air and filter digested tissue using a cell scraper to push the tissue through. Place cells into a 50ml centrifuge tube and spin for 10 mins at 750 rpm. Aspirate off enzyme solution and tap tube gently on bench to dislodge pellet. Add 10 mis of serum containing media (MEM D-val (Gibco) containing 10% foetal bovine serum, 2mM glutamate.
- MEM D-val Gibco
- the neurons, glia and progenitor cells in culture according to the present invention have been further characterised using immunocytochemical markers.
- the neurons have been shown to express ⁇ -tubulin isotype 3, GJAP43 and NCAM (neural cell adhesion molecule). This confirms their neuronal phenotype and provides evidence that they retain some immature characteristics rather than being fully terminally differentiated, mature neurons. They also do not express at significant levels OMP (olfactory marker protein) immunoreactivity.
- OMP is the classic marker of fully differentiated mature olfactory neurons so this provides further confirmation of their immature status.
- the glial cells in culture have been shown to be significantly heterogeneous with the majority of cells expressing S-100 marker protein and the low affinity nerve growth factor receptor which is consistent with them being of the ensheathing cell, peripheral glial phenotype.
- Some of the glial cells express GFAP (glial fibrillary acidic protein) at high levels and are in keeping morphologically with central, astrocytic glial cells.
- the cells of the peripheral glial phenotype also express GFAP but at much lower levels.
- the progenitor cells in culture have been identified by their morphology and intense immunoreactivity for cytokeratin.
- NGF nerve growth factor
- GDNF glial cell line derived neurotrophic factor
- CNTF ciliary neurotrophic factor
- BDNF brain derived neurotrophic factor
- LIF leukemia inhibitory factor
- the recombinant growth factors assayed were from Collaborative Research (NGF), Promega (GDNF, CNTF and BDNF) and Amrad (Esgrow, LIF).
- NGF Collaborative Research
- GDNF Promega
- CNTF CNTF
- BDNF Amrad
- cells were plated as described in the method and the recombinant factors to be assayed added at the first change of media and feed which occurred at 24 hours in culture. Cells were then examined at 5 and 7 days in culture.
- Assays included an overall cell density count on unfixed living cells; and phenotypic analysis and counts of healthy neurons and glia using the immunocytochemical markers B-specific tubulin (neurons), GFAP (glia), cytokeratin (progenitor cells) as well as the marker of olfactory neuronal differentiation, OMP. Preliminary assays showed no significant change from control cultures in the number of cells in the neuronal or glial class or in the number of differentiated neurons.
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41921/97A AU4192197A (en) | 1996-09-16 | 1997-09-16 | Method of cell culture |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO2359A AUPO235996A0 (en) | 1996-09-16 | 1996-09-16 | Method of cell culture |
AUPO2359 | 1996-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998012303A1 true WO1998012303A1 (en) | 1998-03-26 |
Family
ID=3796671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1997/000616 WO1998012303A1 (en) | 1996-09-16 | 1997-09-16 | Method of cell culture |
Country Status (2)
Country | Link |
---|---|
AU (1) | AUPO235996A0 (en) |
WO (1) | WO1998012303A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7312025B2 (en) | 2002-07-12 | 2007-12-25 | University Of Washington | Methods and systems for extended in vitro culture of neuronal cells |
WO2008131368A2 (en) | 2007-04-20 | 2008-10-30 | Acucela Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
WO2009005794A2 (en) | 2007-06-29 | 2009-01-08 | Acucela, Inc. | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
WO2009045479A1 (en) | 2007-10-05 | 2009-04-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
US9133154B2 (en) | 2013-03-12 | 2015-09-15 | Acucela Inc. | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders |
US9447078B2 (en) | 2012-01-20 | 2016-09-20 | Acucela Inc. | Substituted heterocyclic compounds for disease treatment |
CN113388581A (en) * | 2021-07-05 | 2021-09-14 | 中国人民解放军海军军医大学第一附属医院 | Primary cell culture method for sleeve gastrectomy mouse vagus nerve |
-
1996
- 1996-09-16 AU AUPO2359A patent/AUPO235996A0/en not_active Abandoned
-
1997
- 1997-09-16 WO PCT/AU1997/000616 patent/WO1998012303A1/en active Application Filing
Non-Patent Citations (5)
Title |
---|
EXP. NEUROLOGY, 138, (1996), NAKAO N. et al., "Differential Trophic Effects of Basic Fibroblast Growth Factor, Insulin-Like Growth Factor-1 and Neurotrophin-3 on Striatal Neurons in Culture", pages 144-157. * |
GLIAL, (1988), TROPEA M. et al., "Glial Cells Promote Dendritic Development in Rat Sympathetic Neurons In Vitro", pages 380-392. * |
J. BASIC CLIN. PHYSIOL. PHARMACOL., 4(3), (1993), HANANI M., "Neuron and Glial Cells of the Enteric Nervous System: Studies in Tissue Culture", pages 157-179. * |
J. NEUROSCI. RES., 41, (1995), MARTIN F.C. and WILEY C.A., "A Serum-Free Pyruvate-Free Medium that Supports Neonatal Neural/Glial Cultures", pages 246-258. * |
NEURON, 8, (1992), PIXLEY S.K., "CNJS Glial Cells Support In Vitro Survival, Division and Differentiation of Dissociated Olfactony Neuronal Progenitor Cells", pages 1191-1204. * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7312025B2 (en) | 2002-07-12 | 2007-12-25 | University Of Washington | Methods and systems for extended in vitro culture of neuronal cells |
WO2008131368A2 (en) | 2007-04-20 | 2008-10-30 | Acucela Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
US8420863B2 (en) | 2007-04-20 | 2013-04-16 | Acucela, Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
US8653142B2 (en) | 2007-04-20 | 2014-02-18 | Acucela Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
US10201545B2 (en) | 2007-04-20 | 2019-02-12 | Acucela Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
US9314467B2 (en) | 2007-04-20 | 2016-04-19 | Acucela Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
US9421210B2 (en) | 2007-04-20 | 2016-08-23 | Acucela Inc. | Styrenyl derivative compounds for treating ophthalmic diseases and disorders |
WO2009005794A2 (en) | 2007-06-29 | 2009-01-08 | Acucela, Inc. | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
EP3210966A1 (en) | 2007-10-05 | 2017-08-30 | Acucela, Inc. | Alkoxyphenylpropylamines for the treatment of age-related macular degeneration |
WO2009045479A1 (en) | 2007-10-05 | 2009-04-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
US9447078B2 (en) | 2012-01-20 | 2016-09-20 | Acucela Inc. | Substituted heterocyclic compounds for disease treatment |
US9133154B2 (en) | 2013-03-12 | 2015-09-15 | Acucela Inc. | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders |
CN113388581A (en) * | 2021-07-05 | 2021-09-14 | 中国人民解放军海军军医大学第一附属医院 | Primary cell culture method for sleeve gastrectomy mouse vagus nerve |
CN113388581B (en) * | 2021-07-05 | 2023-03-07 | 中国人民解放军海军军医大学第一附属医院 | Primary cell culture method for sleeve gastrectomy mouse vagus nerve |
Also Published As
Publication number | Publication date |
---|---|
AUPO235996A0 (en) | 1996-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McMorris | Cyclic AMP induction of the myelin enzyme 2′, 3′‐cyclic nucleotide 3′‐phosphohydrolase in rat oligodendrocytes | |
Gingras et al. | Optimized protocols for isolation of primary motor neurons, astrocytes and microglia from embryonic mouse spinal cord | |
Lemieux et al. | Characterization and purification of a primitive hematopoietic cell type in adult mouse marrow capable of lymphomyeloid differentiation in long-term marrow" switch" cultures | |
Chen et al. | Effect of taurine on human fetal neuron cells: proliferation and differentiation | |
JP4371179B2 (en) | Lineage-restricted neuron precursor | |
US6395546B1 (en) | Generation of dopaminergic neurons from human nervous system stem cells | |
Zhang et al. | Self‐renewing canine oligodendroglial progenitor expanded as oligospheres | |
Niapour et al. | Novel method to obtain highly enriched cultures of adult rat Schwann cells | |
Tao | Isolation and culture of Schwann cells | |
Wei et al. | An improved method for isolating Schwann cells from postnatal rat sciatic nerves | |
Zeng et al. | Co-transplantation of schwann cells promotes the survival and differentiation of neural stem cells transplanted into the injured spinal cord | |
CA2371260A1 (en) | Materials and methods relating to neuronal development | |
WO1997007200A1 (en) | Adult oligodendrocyte precursor cell compositions and methods | |
WO1997007200A9 (en) | Adult oligodendrocyte precursor cell compositions and methods | |
Kerk et al. | Two classes of primitive pluripotent hemopoietic progenitor cells: separation by adherence | |
WO2004108907A1 (en) | Nerve cell obtained by electrically pulse-treating es cell | |
WO1998012303A1 (en) | Method of cell culture | |
Zhang et al. | Isolation of neural crest‐derived stem cells from rat embryonic mandibular processes | |
WO2006028049A1 (en) | Method of producing adaptation medium for astrocyte-like cells | |
US6576465B1 (en) | Human bone accessory cells | |
Lopez et al. | Isolation and serum-free culture of primary Schwann cells from human fetal peripheral nerve | |
Shimada | Suppression of myogenesis by heterotypic and heterospecific cells in monolayer cultures | |
Lelkes et al. | Culture of neuroendocrine and neuronal cells for tissue engineering | |
Hooghe-Peters et al. | Co-culture of nerve cells and pancreatic islets | |
CN101848992B (en) | Use of the opposite cell differentiation program (OCDP) for the treatment of degenerated organs in the pathological state |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV GH Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998514078 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |